NKure Therapeutics and CRISPR Therapeutics partner to develop off-the-shelf CAR T therapy CTX112 in India

Metabolic Rewiring Enhances CAR-T Cells for Solid Tumor Immunotherapy

By harnessing the metabolic power of a molecule more commonly recognized for its function in immune regulation, scientists from Fudan University Shanghai have discovered a new method to enhance chimeric antigen receptor (CAR)-T cells. The Cell Metabolism study demonstrated that expressing the transcription factor Foxp3 and a CAR construct fortifies T cells against the harsh, nutrient-starved tumor microenvironment (TME) and preserves their killi…

NKure Therapeutics and CRISPR Therapeutics partner to develop off-the-shelf CAR T therapy CTX112 in India

Bengaluru-based cell and gene therapy startup NKure Therapeutics and gene-based medicine company CRISPR Therapeutics have announced a strategic partnership to co-develop and co-commercialise CTX112, an allogeneic CAR T therapy, for oncology indications in India. The partnership is aimed at expanding access to CAR T therapies for patients with B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and other non-Hodgkin’s lymphomas. …